Medicinski Dusikov Oksid Messer (Nitric Oxide)

Medicinski Dusikov Oksid Messer (inhaled nitric oxide) acts as a selective pulmonary vasodilator for conditions involving elevated pulmonary arterial pressure.

• Neonatal pulmonary hypertension: reduces pulmonary artery pressure and improves oxygenation in newborns.
• Acute respiratory distress syndrome: provides selective pulmonary vasodilation to enhance ventilation‑perfusion matching.
• Persistent pulmonary hypertension of the newborn: lowers right‑ventricular afterload and supports systemic oxygen delivery.

• Inhaled nitric oxide diffuses into the pulmonary vasculature where it activates soluble guanylate cyclase in smooth‑muscle cells. This increases cyclic guanosine monophosphate (cGMP) levels, leading to relaxation of pulmonary arterial smooth muscle and selective reduction of pulmonary vascular resistance without systemic vasodilation. The effect is rapid, reversible, and confined to the lungs because nitric oxide is rapidly bound by hemoglobin, limiting systemic exposure.

Inhaled nitric oxide may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Methemoglobinemia: elevation of methemoglobin levels causing reduced oxygen‑carrying capacity.
• Nitrogen dioxide formation: accumulation of NO₂ in the breathing circuit leading to airway irritation.
• Rebound pulmonary hypertension: sudden increase in pulmonary pressure after abrupt discontinuation.
• Hypotension: systemic blood pressure reduction, especially with high doses.

Serious or Rare Side Effects

• Severe hypotension: profound drop in systemic blood pressure requiring intervention.
• Pulmonary hemorrhage: bleeding within the lungs, particularly in preterm infants.
• Seizures: neurologic events possibly related to elevated methemoglobin.
• Toxicity from nitrogen dioxide: severe airway injury due to high NO₂ concentrations.

When using Medicinski Dusikov Oksid Messer, clinicians should observe several safety measures to minimize risks.

• Monitor methemoglobin: regularly check blood methemoglobin levels during therapy.
• Avoid abrupt discontinuation: taper the dose to prevent rebound pulmonary hypertension.
• Use compatible delivery system: ensure the ventilator circuit includes NO₂ scavenging capability.
• Caution in anemia: patients with severe anemia may be more susceptible to methemoglobinemia.
• Contraindicated in severe pulmonary hemorrhage: avoid use in patients with active lung bleeding.
• Store at ambient temperature: keep cylinders in a well‑ventilated, dry area, protected from direct sunlight and extreme temperatures.

Inhaled nitric oxide can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Phosphodiesterase‑5 inhibitors (e.g., sildenafil): may cause excessive systemic hypotension.
• Other pulmonary vasodilators (e.g., prostacyclin analogues): additive vasodilatory effect increasing risk of hypotension.
• Nitric oxide donors (e.g., nitroglycerin): combined use can lead to severe hypotension.

Moderate Interactions (Monitor Closely)

• Anticoagulants: heightened risk of pulmonary hemorrhage when combined with inhaled NO.
• Inhaled anesthetics (e.g., sevoflurane): may potentiate hypotensive response.
• High inspired oxygen concentrations: increase formation of nitrogen dioxide, requiring monitoring.